Innova Captab Q4FY26 Results: Net profit rises 41% YoY to ₹403.5 crore
- Innova Captab revised Q4FY26 and FY26 results due to deferred tax accounting errors
- Consolidated net profit rose 41% YoY to ₹403.5 crore for Q4FY26
- Full-year revenue grew to ₹16,300.2 million, up from ₹12,436.8 million in FY25
- Board approved ₹45 crore brownfield expansion at Baddi facility
- Auditor B S R & Co. LLP issued unmodified opinion on revised results

*this image is generated using AI for illustrative purposes only.
Innova Captab revised its consolidated financial results for the quarter and fiscal year ended March 31, 2026, following the identification of inadvertent accounting errors. The Board of Directors approved the restated figures on August 21, 2026, alongside a plan to expand its manufacturing capacity in Himachal Pradesh.
The revisions primarily involved the retrospective correction of deferred tax liabilities related to a historical business combination and the recognition of a deferred tax asset under Section 80JJAA of the Income Tax Act. Additionally, the company reclassified ₹185.08 million in supplier finance arrangements from trade payables to other financial liabilities.
Revised Financial Performance
For the quarter ended March 31, 2026, consolidated revenue from operations stood at ₹4,478.02 million, up from ₹3,147.41 million in the corresponding quarter of the previous year. Consolidated net profit for the period rose to ₹403.49 million, compared to ₹285.66 million in Q4FY25.
| Metric | Q4FY26 (Revised) | Q4FY25 (Restated) | Change |
|---|---|---|---|
| Revenue from operations | ₹4,478.02 million | ₹3,147.41 million | +42.3% |
| Net Profit | ₹403.49 million | ₹285.66 million | +41.2% |
| Earnings Per Share | ₹7.05 | ₹4.99 | +41.3% |
For the full fiscal year ended March 31, 2026, consolidated revenue reached ₹16,300.18 million, an increase from ₹12,436.76 million in FY25. Net profit for the year was reported at ₹1,431.83 million, up from ₹1,272.51 million in the prior year.
What the Numbers Show
The revision of the deferred tax liability related to the acquisition of Sharon Bio-Medicine Limited had a material impact on equity. As of April 1, 2024, total assets were reduced by ₹105.37 million due to this correction. Similarly, for the year ended March 31, 2025, deferred tax expense increased by ₹10.07 million, reducing the previously reported profit for the year by the same amount. The recognition of the Section 80JJAA tax asset in FY26 reduced the total tax expense by ₹22.66 million compared to the originally approved figures, thereby boosting the reported net profit.
Capacity Expansion Plan
The Board approved a brownfield expansion of the manufacturing facility located at Baddi, Himachal Pradesh. The project involves adding two Oral Solid Dosage production lines to the existing infrastructure, which currently operates at approximately 85% to 90% capacity utilization.
- Investment: Approximately ₹45 crore
- Financing: Bank credit facilities and internal accruals
- Timeline: Expected completion within 18 to 22 months
The expansion aims to improve operational efficiency and support long-term growth strategies. Statutory auditors B S R & Co. LLP issued an unmodified opinion on the revised standalone and consolidated financial results.
Historical Stock Returns for Innova Captab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.40% | +3.91% | +11.84% | +62.58% | +20.91% | +101.05% |
How will the recognition of the Section 80JJAA tax asset impact Innova Captab's future effective tax rates and cash flow projections?
What specific market opportunities or client contracts is the new Himachal Pradesh capacity expansion intended to capture upon completion?
Could the recent accounting restatements affect investor confidence or trigger any regulatory scrutiny regarding internal financial controls?

































